Patents by Inventor Brunangelo Falini

Brunangelo Falini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF
    Publication number: 20230212680
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML).
    Type: Application
    Filed: April 26, 2022
    Publication date: July 6, 2023
    Inventors: Brunangelo Falini, Cristina Mecucci
  • Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
    Patent number: 11337983
    Abstract: The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: May 24, 2022
    Inventors: Brunangelo Falini, Maria Paola Martelli
  • Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
    Patent number: 11077139
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: August 3, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITA DI PERUGIA, AMERICAN UNIVERSITY OF BEIRUT, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Hugues De The, Ali Bazarbachi, Hiba El Hajj, Maria Paula Martelli, Brunangelo Falini
  • NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF
    Publication number: 20200032354
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML).
    Type: Application
    Filed: October 10, 2019
    Publication date: January 30, 2020
    Inventors: Brunangelo Falini, Cristina Mecucci
  • Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof
    Patent number: 10487366
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML).
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: November 26, 2019
    Inventors: Brunangelo Falini, Cristina Mecucci
  • DACTINOMYCIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
    Publication number: 20190314380
    Abstract: The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.
    Type: Application
    Filed: May 21, 2019
    Publication date: October 17, 2019
    Inventors: Brunangelo Falini, Maria Paola Martelli
  • Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
    Patent number: 10335416
    Abstract: The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: July 2, 2019
    Inventors: Brunangelo Falini, Maria Paola Martelli
  • Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof
    Patent number: 10155989
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML).
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: December 18, 2018
    Inventors: Brunangelo Falini, Cristina Mecucci
  • DACTINOMYCIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
    Publication number: 20180207168
    Abstract: The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.
    Type: Application
    Filed: September 13, 2016
    Publication date: July 26, 2018
    Inventors: Brunangelo FALINI, Maria Paola MARTELLI
  • NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF
    Publication number: 20180119233
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML).
    Type: Application
    Filed: December 18, 2017
    Publication date: May 3, 2018
    Inventors: Brunangelo Falini, Cristina Mecucci
  • Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof
    Patent number: 9725767
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML).
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: August 8, 2017
    Assignee: Trovagene, Inc.
    Inventors: Brunangelo Falini, Cristina Mecucci
  • COMBINATION OF AN ARSENIC COMPOUND AND AT LEAST ONE RETINOID FOR TREATING ACUTE MYELOID LEUKEMIA
    Publication number: 20160317579
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid.
    Type: Application
    Filed: December 30, 2014
    Publication date: November 3, 2016
    Inventors: Hugues De The, Ali Bazarbachi, Hiba El Hajj, Maria Paula Martelli, Brunangelo Falini
  • Method for monitoring minimal residual hairy cell leukemia
    Patent number: 9222137
    Abstract: The present invention relates to hairy cell leukemia biomarkers and methods of utilizing these biomarkers to diagnose and/or treat hairy cell leukemia.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: December 29, 2015
    Assignee: Trovagene, Inc.
    Inventors: Enrico Tiacci, Brunangelo Falini, Raul Rabadan
  • NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF
    Publication number: 20150368726
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML).
    Type: Application
    Filed: June 25, 2015
    Publication date: December 24, 2015
    Inventors: Brunangelo Falini, Cristina Mecucci
  • NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF
    Publication number: 20150184245
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML)
    Type: Application
    Filed: August 6, 2013
    Publication date: July 2, 2015
    Inventors: Brunangelo Falini, Cristina Mecucci
  • Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof
    Patent number: 8501924
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML).
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: August 6, 2013
    Inventors: Brunangelo Falini, Cristina Mecucci
  • Methods of Detecting BRAF Mutations in Cancer
    Publication number: 20130130264
    Abstract: The present disclosure relates to detecting BRAF mutations and methods of utilizing BRAF mutations to diagnose cancer.
    Type: Application
    Filed: October 24, 2012
    Publication date: May 23, 2013
    Inventors: Enrico Tiacci, Brunangelo Falini
  • Hairy Cell Leukemia Biomarkers and Methods of Using Same
    Publication number: 20130064789
    Abstract: The present invention relates to hairy cell leukemia biomarkers and methods of utilizing these biomarkers to diagnose and/or treat hairy cell leukemia.
    Type: Application
    Filed: May 10, 2012
    Publication date: March 14, 2013
    Inventors: Brunangelo Falini, Raul Rabadan, Enrico Tiacci
  • Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof
    Patent number: 8222370
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML).
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: July 17, 2012
    Inventors: Brunangelo Falini, Cristina Mecucci
  • Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof
    Publication number: 20090297543
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML).
    Type: Application
    Filed: October 28, 2005
    Publication date: December 3, 2009
    Inventors: Brunangelo Falini, Cristina Mecucci